Advancing the technology of septal occlusion
The Carag Bioresorbable Septal Occluder (CBSO) is a breakthrough device that advances septal occluder technology to a new level.
Transcatheter device closure of atrial level shunts is a standard of care throughout the world, and the treatment of choice for most patients. Current septal implants utilized a metal framework to support occlusive material and to 'grasp' the septum, holding the device in place. CBSO employs a device framework that 'goes away' after fulfilling its primary function following implantation.
CBSO is not currently available in the United States.
Metal free, fully bioresorbable PLGA framework
- No metal framework: Reduces risks of erosion, perforation, valve distortion
- Preserves atrial septum for future transseptal access
- Predictable resorption timeline after endothelialisation
- Framework fully resorbed within 24 months
- No Nitinol, no nickel
- Designed and manufactured in Switzerland
- CE marked
- Contact us if you think CBSO is the right choice for your child, your loved ones or yourself
Bioresorbable devices are the definite future of treating congenital and structural heart disease. With the Carag Bioresorbable Septal Occluder (CBSO) we are opening this new clinical chapter and might treat atrial septal defects in patients of all ages with a new device, that is soft, thin and has no metal structure (e.g. nitinol wires). This might influence and improve long term performance of implants, especially in children.
Prof. Dr. Stephan Schubert, Pediatric Cardiologist and Interventionalist, Berlin
The CBSO is really a breakthrough! Since decades we have been waiting for a resorbable device for transcatheter closures. Patients have already heard about this resorbable device and are asking about its availability. I am looking forward to finally providing this alternative to my patients.
Prof. Dr. Horst Sievert, Interventional cardiologist, Frankfurt